Harshad Mehta
Cardiovascular Disease · Pittsburgh, PANPI 1942281217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,481 and has fallen 98.2% since, to $26 in 2024.
Across 117 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$352
- Novartis$291
- Biotronik Inc.$272
- Pfizer$255
- Amgen$147
- E.r. Squibb & Sons, L.L.C.$123
- plus $480 from 13 others
What the payments were for
- Food & beverage$1,84996%
- Education$704%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $352 |
| Novartis | 19 | $291 |
| Biotronik Inc. | 8 | $272 |
| Pfizer | 16 | $255 |
| Amgen | 9 | $147 |
| E.r. Squibb & Sons, L.L.C. | 10 | $123 |
| Sanofi-aventis U.S. LLC | 8 | $111 |
| Boston Scientific | 4 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 3 | $42 |
| AstraZeneca | 3 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $26 |
| Novo Nordisk | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Abbott | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,920 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Pittsburgh
- George GabrielPittsburgh$563K
- Mark GreathousePittsburgh$243K
- Brian HenryPittsburgh$224K
- Kent VolosinPittsburgh$190K
- Victor FarahPittsburgh$98K
- Moneal ShahPittsburgh$90K
- Stephen ChanPittsburgh$70K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.